TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32536683
Drug: G‐aenial immersed
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐aenial immersed in coffee
Study: 32536683
Drug: G‐aenial immersed
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐aenial immersed in tomato sauce
Study: 32536683
Drug: G‐aenial after
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐aenial after polishing
Study: 34887918
Drug: Microneedling plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling plus topical pimecrolimus 1%
Study: 34887918
Drug: Topical pimecrolimus
Normalized name: pimecrolimus Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pimecrolimus 1%
Study: 33674858
Drug: Positive framing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive framing warning (e.g., '7 out of 10 people will not experience nausea')
Study: 33674858
Drug: Negative framing
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative framing warning (e.g., '3 out of 10 people will experience nausea')
Study: 33674858
Drug: General warning
Approvals — FDA: no, EMA: no, PMDA: no
Description: General warning (e.g., 'a proportion of people will experience nausea')
Study: 36267499
Drug: SOC+pegfilgrastim (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC+pegfilgrastim (0.6 mg subcutaneously on Day 1 and Day 8)
Study: 33428221
Drug: Hyperbaric prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric prilocaine (60 mg intrathecal)
Study: 33428221
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (12.5 mg intrathecal)
Study: 36226998
Drug: Double acupoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double acupoint combination therapy (TN PC6 combined with ST36)
Study: 34546300
Drug: Enteral L
Normalized name: PediaSure Enteral Liquid Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral L rhamnosus GG (1 × 10^10 colony-forming units) twice daily in the ICU (n = 1321)
Study: 34546300
Drug: Enteral L
Normalized name: PediaSure Enteral Liquid Vanilla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral L rhamnosus GG
Study: 35848844
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation associated with abdominal electrical stimulation (EE) via 8‐ and 20‐Hz Functional Electrical Stimulation (FES) of the abdominal muscles for 30 minutes daily for two weeks
Study: 34781770
Drug: Wearable resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable resistance (WR) on lower legs during warm-up (200 g to 600 g)
Study: 33755728
Drug: Continued subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued subcutaneous semaglutide 2.4 mg once weekly
Study: 32897034
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of brensocatib
Study: 32897034
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of brensocatib
Study: 32897034
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg and 25 mg of brensocatib
Study: 33497364
Drug: Tetravalent‐inactivated influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent‐inactivated influenza vaccine (TIV)
Study: 32727225
Drug: Gamma tocopherol-enriched
Normalized name: gamma-Tocopherol
DrugBank: gamma-Tocopherol (DB15394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma tocopherol-enriched supplement
Study: 33690909
Drug: Placebo 'anaesthetic'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 'anaesthetic' cream
Study: 32007996
Drug: Exercise snacks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise snacks (6 × 1 min of resistance‐based activities) 3 times daily for 3 months with glutamine (0.5 g/kg/day)
Study: 32007996
Drug: Exercise snacks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise snacks (6 × 1 min of resistance‐based activities) 3 times daily for 3 months with placebo
Study: 33411466
Drug: Cefazolin monotherapy
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin monotherapy
Study: 33411466
Drug: Cefazolin and
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin and aminoglycoside therapy
Study: 34921690
Drug: Static computer-aided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static computer-aided implant surgery (s-CAIS)
Study: 34921690
Drug: Conventional implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implant surgery (CIS)
Study: 33430772
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg IVI in 100 ml normal saline (D group)
Study: 34324113
Drug: No post-mastectomy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No post-mastectomy radiation therapy (no PMRT)
Study: 32921065
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment with IEPED)
Study: 32438250
Drug: Pelvic suspension
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic suspension
Study: 33196101
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction strategy for adalimumab, etanercept and ustekinumab
Study: 33172225
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg (Group 2)
Study: 35428982
Drug: ACE‐083 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE‐083 240 mg/muscle injected bilaterally every 3 weeks in the biceps brachii (BB) muscles
Study: 35428982
Drug: ACE‐083 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE‐083 240 mg/muscle injected bilaterally every 3 weeks in the tibialis anterior (TA) muscles
Study: 32614702
Drug: Docetaxel-based chemotherapy
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel-based chemotherapy
Study: 35057416
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate (SP) supplementation (50 mg·kg−1 of FFM/day)
Study: 39742913
Drug: HFNC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC at 60 L/min
Study: 39742913
Drug: HFNC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC at 40 L/min
Study: 32291309
Drug: Baseline (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (no therapy)
Study: 32291309
Drug: HFNC (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNC (20, 40, and 60 L/min)
Study: 32291309
Drug: Conventional nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional nasal prongs at 5 L/min
Study: 34019483
Drug: CAU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAU plus one dose of 0.1 mg/kg oral ondansetron
Study: 34019483
Drug: CAU (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAU (oral rehydration therapy)
Study: 34941339
Drug: Life Review
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life Review Therapy (LRT-HS), approximately 20 sessions including structured life review, narrative exposure, cognitive and behavioral elements.
Study: 35410322
Drug: Paracetamol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol treatment
Study: 34014688
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement and cognitive behavioral therapies plus adjunctive pharmacotherapy
Study: 34014688
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement and cognitive behavioral therapies plus placebo
Study: 35782469
Drug: Vaccine hesitancy
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine hesitancy due to misinformation, conspiracies, myths, and rumors about side effects of vaccination.
Study: 39654273
Drug: Tenecteplase (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (0.25 mg/kg)
Study: 32049857
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment (14 sessions over 2 weeks) with anti-depressant treatment
Study: 32049857
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control group receiving only anti-depressant treatment
Study: 35672690
Drug: liposomal MTP-PE
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposomal MTP-PE in combination with ifosfamide
Study: 36253042
Drug: Functional relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional relaxation (FR) therapy, implemented as group therapy, 12 sessions led by a certified physiotherapist once a week.
Study: 36253042
Drug: Placebo relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo relaxation intervention for the same duration as the FR therapy.
Study: 36253042
Drug: Functional relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional relaxation (FR) therapy
Study: 35679461
Drug: Sodium hypochlorite
Normalized name: Sodium hypochlorite
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium hypochlorite solution (5.25%)
Study: 35679461
Drug: Gel-based formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-based formulation of sodium hypochlorite
Study: 35795100
Drug: Ultrasound-guided paravertebral
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided paravertebral block (PVB) followed by sufentanil patient-controlled intravenous analgesia (PCIA)
Study: 35795100
Drug: Sufentanil patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil patient-controlled intravenous analgesia (PCIA) only
Study: 35251438
Drug: Acupuncture (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (10 weekly sessions of manual Acupuncture)
Study: 35251438
Drug: Sham Acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Acupuncture (10 weekly sessions of Sham Acupuncture)
Study: 35598359
Drug: Olaparib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (300 mg bid)
Study: 35220180
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received intravenous tenoxicam and paracetamol, with morphine via patient‐controlled analgesia)
Study: 32000786
Drug: Anopheles gambiae
Normalized name: ANOPHELES QUADRIMACULATUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anopheles gambiae s.l. tested by ELISA
Study: 32141365
Drug: Passive music
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive music therapy during catheter placement and post-procedure (30-45 min during placement, twice a day for 30 min until discharge)
Study: 35084480
Drug: Plinabulin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plinabulin, 40 mg
Study: 35084480
Drug: Pegfilgrastim, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim, 6 mg
Study: 33731209
Drug: GV-971 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV-971 (900 mg)
Study: 37323059
Drug: GSK2831781 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2831781 450 mg IV
Study: 36088650
Drug: GSK2831781 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2831781 150 mg SC
Study: 36088650
Drug: GSK2831781 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2831781 450 mg SC
Study: 33485464
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg intravenously once every 2 weeks) plus ipilimumab (1 mg/kg intravenously once every 6 weeks) for up to 2 years
Study: 33485464
Drug: Chemotherapy (pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (pemetrexed [500 mg/m2 intravenously] plus cisplatin [75 mg/m2 intravenously] or carboplatin [area under the concentration‐time curve 5 mg/mL per min intravenously]) once every 3 weeks for up to six cycles
Study: 32811682
Drug: PARP inhibitors
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitors overall
Study: 33128473
Drug: 1% LT-BOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% LT-BOL cream
Study: 35397122
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative chemotherapy
Study: 35923425
Drug: B-EV71 vaccine
Normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-EV71 vaccine (Older-B group)
Study: 35923425
Drug: C-EV71 vaccine
Normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-EV71 vaccine (Older-C group)
Study: 35923425
Drug: B-EV71 vaccine
Normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-EV71 vaccine (Younger-B group)
Study: 34571023
Drug: CNS stimulants
Normalized name: CNS STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS stimulants
Study: 32342857
Drug: 30 ml/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml/kg/day feed increments
Study: 32342857
Drug: 18 ml/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 ml/kg/day feed increments
Study: 35299968
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, Bifidobacterium animalis subsp. lactis CP-9) administered daily for 6 months along with regular insulin therapy.
Study: 35299968
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (insulin therapy without probiotics).
Study: 33235307
Drug: Protonated nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protonated nicotine (18 mg/mL, medium protonation) e-liquid
Study: 33235307
Drug: Nicotine benzoate
Normalized name: nicotine benzoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine benzoate formulation (30 mg/mL nicotine, high protonation)
Study: 36226244
Drug: MTX and
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX and LEF combination therapy
Study: 34543098
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg daily dose of linezolid
Study: 34543098
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg daily dose of linezolid
Study: 33814474
Drug: EMG BF
Normalized name: BF-844
DrugBank: BF-844 (DB17801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG BF training combined with conventional physical therapy (n=17)
Study: 33814474
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (Control group, n=16)
Study: 32807615
Drug: One-stage lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage lateral thoracodorsal flap with an implant
Study: 32807615
Drug: Latissimus dorsi
Normalized name: Saccharina latissima extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latissimus dorsi reconstruction combined with an implant
Study: 32880468
Drug: Up-front resection
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-front resection with adjuvant chemotherapy
Study: 33047216
Drug: Cemdisiran (50–900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemdisiran (50–900 mg single doses or 100–600 mg repeat doses)
Study: 33047216
Drug: Cemdisiran (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemdisiran (200 or 400 mg weekly)
Study: 33047216
Drug: Eculizumab (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (900 or 1200 mg biweekly)
Study: 33047216
Drug: Cemdisiran (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemdisiran (600 mg)
Study: 33047216
Drug: Cemdisiran (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemdisiran (various doses)
Study: 33394852
Drug: Paxos Scope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paxos Scope (smartphone-based ophthalmic camera)
Study: 33885775
Drug: Hydroxychloroquine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (800 mg loading dose, then 400 mg daily for 9 days)
Study: 33885775
Drug: Lopinavir-ritonavir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir-ritonavir (800 mg and 200 mg loading dose every 12 hours, followed by 400 mg and 100 mg every 12 hours for 9 days)
Study: 33012605
Drug: BK-SE36/CpG (full-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BK-SE36/CpG (full-dose)
Study: 33012605
Drug: BK-SE36/CpG (half-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BK-SE36/CpG (half-dose)
Study: 34797597
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of tranexamic acid
Study: 34797597
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Kligman combination drug
Study: 34548284
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (mean HbA1c 7.2%)
Study: 34548284
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (mean HbA1c 9.0%)
Study: 34548284
Drug: DCCT conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCCT conventional therapy
Study: 36416841
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (2000 international units daily)
Study: 36161344
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (700 IU) plus Calcium (500 mg) daily for 3 years
Study: 36161344
Drug: Placebo (double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (double placebo) daily for 3 years
Study: 34628916
Drug: Sitting and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting and lying Liuzijue exercise (LG) for 3 months, 30 minutes twice daily.
Study: 34628916
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment and nursing (CG)
Study: 35689818
Drug: Oral sulphate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulphate tablets (OST)
Study: 33849367
Drug: Dexmedetomidine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (Group D, 1 μg/kg before, and 0.6 μg/kg/hour during procedure)
Study: 33849367
Drug: Midazolam (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (Group M, 2 mg before procedure)
Study: 32960773
Drug: Digital devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital devices for information delivery (tablet computers, e-learning platforms, public website)
Study: 33586513
Drug: G +
Normalized name: Citracal 250 mg + D
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + chemo
Study: 35015065
Drug: Written Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written Exposure Therapy (5 weekly sessions)
Study: 35015065
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (12 twice-weekly sessions)
Study: 35180287
Drug: Intensive exercise
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive exercise intervention (two daily sessions of moderate-intensity exercises)
Study: 34164887
Drug: Ato‐Oxy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ato‐Oxy plus zolpidem (10 mg)
Study: 36251422
Drug: Renin-Angiotensin System
Normalized name: Renin-angiotensin system inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-Angiotensin System Inhibitors (RASi)
Study: 36251422
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker or thiazide diuretic (control)
Study: 34560015
Drug: PXL770 250
Normalized name: PXL770 free acid anhydrous
DrugBank: PXL-770 free acid anhydrous (DB17615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXL770 250 mg once daily
Study: 34560015
Drug: PXL770 250
Normalized name: PXL770 free acid anhydrous
DrugBank: PXL-770 free acid anhydrous (DB17615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXL770 250 mg twice daily
Study: 34560015
Drug: PXL770 500
Normalized name: PXL770 free acid anhydrous
DrugBank: PXL-770 free acid anhydrous (DB17615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PXL770 500 mg once daily
Study: 36314868
Drug: LHF-535 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHF-535 (0.3 mg/kg to 40 mg/kg single ascending dose)
Study: 36314868
Drug: LHF-535 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHF-535 (450 mg/day, 900 mg/day, 1,125 mg/day for 14 days, with a loading dose of 2,250 mg for the first dose in the 1,125 mg/day cohort)
Study: 36031789
Drug: Dolutegravir-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir-based therapy
Study: 33920232
Drug: AREDS formulation
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AREDS formulation with added DHA, lutein, zeaxanthin, resveratrol, and hydroxytyrosol (intervention group)
Study: 33920232
Drug: AREDS formulation
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AREDS formulation (control group)
Study: 34601160
Drug: TXA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA plus topical CSS
Study: 33823461
Drug: Baseline WMHv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline WMHv (1.62 mL median, IQR 0.66–3.98 mL)
Study: 32742143
Drug: Group cessation
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cessation intervention plus pharmacotherapy